34P Investigating the potential of auger electron-emitting radionuclide-labelled Hsp90 inhibitors in the treatment of cancer
Auger electron (AE) therapy is an emerging treatment in the radiation field; AEs have low energy and travel a short, linear trajectory when emitted, making them ideal for specific irradiation of cancer. However, for AEs to be effective killers of cancer, they must be bound to agents that target cancer cells. Hsp90 is an ATP-dependent molecular chaperone that aids in the folding and stabilization of proteins. Cancer cells express mutated proteins that have an enhanced dependence on chaperones such as Hsp90, and therefore, Hsp90 inhibitors are being developed for use as an anti-cancer drug.
Authors
- Mario Rueda
- Frank Wuest (ORCID: https://orcid.org/0000-0002-6705-6450)
- Allen Kennedy (ORCID: https://orcid.org/0000-0002-2132-7825)
- Paul LaPointe (ORCID: https://orcid.org/0000-0002-5465-1795)
- V. Mancinelli
Institutions
- University of Alberta (CA)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104192
- Primary Topic
- Heat shock proteins research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- Department of Biotechnology, Ministry of Science and Technology, India
- The Wellcome Trust DBT India Alliance